Diversified Trust Co increased its position in Elanco Animal Health (NYSE:ELAN) by 9.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 75,123 shares of the company’s stock after buying an additional 6,754 shares during the quarter. Diversified Trust Co’s holdings in Elanco Animal Health were worth $1,998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently added to or reduced their stakes in ELAN. Steward Partners Investment Advisory LLC bought a new stake in Elanco Animal Health in the second quarter valued at approximately $32,000. Capital Investment Advisory Services LLC boosted its holdings in shares of Elanco Animal Health by 1,501.4% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 1,121 shares of the company’s stock worth $36,000 after buying an additional 1,051 shares in the last quarter. Valeo Financial Advisors LLC boosted its holdings in shares of Elanco Animal Health by 376.7% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,430 shares of the company’s stock worth $48,000 after buying an additional 1,130 shares in the last quarter. Zions Bancorporation N.A. boosted its holdings in shares of Elanco Animal Health by 68.1% during the 2nd quarter. Zions Bancorporation N.A. now owns 1,750 shares of the company’s stock worth $59,000 after buying an additional 709 shares in the last quarter. Finally, Citizens Financial Group Inc RI boosted its holdings in shares of Elanco Animal Health by 26.5% during the 2nd quarter. Citizens Financial Group Inc RI now owns 1,875 shares of the company’s stock worth $63,000 after buying an additional 393 shares in the last quarter.
A number of equities analysts have issued reports on the company. Cleveland Research restated a “hold” rating on shares of Elanco Animal Health in a report on Thursday, September 26th. ValuEngine upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Barclays started coverage on Elanco Animal Health in a report on Monday, September 23rd. They set an “overweight” rating and a $36.00 price target on the stock. Goldman Sachs Group started coverage on Elanco Animal Health in a report on Monday, September 9th. They issued a “positive” rating on the stock. They noted that the move was a valuation call. Finally, UBS Group upgraded Elanco Animal Health from a “sell” rating to a “neutral” rating and cut their target price for the stock from $31.00 to $30.00 in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the stock. Elanco Animal Health currently has an average rating of “Hold” and a consensus price target of $33.98.
Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Tuesday, August 13th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.02. The business had revenue of $781.60 million during the quarter, compared to analyst estimates of $781.49 million. Elanco Animal Health had a return on equity of 7.83% and a net margin of 4.69%. Elanco Animal Health’s revenue was up 1.5% compared to the same quarter last year. On average, research analysts expect that Elanco Animal Health will post 1.08 EPS for the current year.
In other news, insider Michael-Bryant Hicks acquired 11,030 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was bought at an average price of $26.65 per share, with a total value of $293,949.50. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Dawei Li bought 1,384,717 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was bought at an average price of $1.05 per share, with a total value of $1,453,952.85. Over the last ninety days, insiders have bought 1,497,497 shares of company stock valued at $4,457,115. Insiders own 0.04% of the company’s stock.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Featured Story: What is a Call Option?
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.